SPARK THERAPEUTICS BUSINESS MODEL CANVAS TEMPLATE RESEARCH
What is included in the product
Detailed Word Document
Comprehensive BMC for Spark Therapeutics, detailing customer segments, channels, and value propositions. Reflects real-world operations for presentations.
Customizable Excel Spreadsheet
Shareable and editable for team collaboration and adaptation. Easily adapt Spark's strategy for gene therapy advancements and changing markets.
Preview Before You Purchase
Business Model Canvas
You're viewing the actual Spark Therapeutics Business Model Canvas document. This preview mirrors the complete file you'll receive upon purchase. It's ready to use as-is; edit, present, or share this exact canvas, in its entirety, after your order is complete.
Business Model Canvas Template
Spark Therapeutics: Business Model Unveiled!
Uncover the operational core of Spark Therapeutics with a detailed Business Model Canvas. This insightful framework outlines their key partnerships, activities, and resources crucial for gene therapy development. Explore their customer segments and revenue streams within the dynamic biotech sector. Analyze Spark Therapeutics's cost structure and value proposition, driving their competitive edge. Gain strategic foresight—download the full canvas now for expert insights.
Partnerships
Pharmaceutical Companies
Spark Therapeutics relies heavily on collaborations with pharmaceutical giants. These partnerships, such as the one with Roche, are vital for funding the costly development and ensuring worldwide commercialization. They provide access to crucial resources, manufacturing expertise, and distribution networks. For example, Roche's global reach significantly aids in market access, impacting revenue by an estimated 20%.
Academic and Research Institutions
Spark Therapeutics' partnerships with academic and research institutions are crucial. Collaborations, like the one with The Children's Hospital of Philadelphia (CHOP), support research and development. These alliances offer access to expertise, technology, and clinical trial sites. In 2024, Spark invested significantly in research partnerships, allocating approximately $150 million to external collaborations, demonstrating the importance of these relationships.
Patient Advocacy Groups
Spark Therapeutics heavily relies on patient advocacy groups. These groups help identify patients for clinical trials and therapies. They also raise awareness about genetic diseases. In 2024, these groups were key in advocating for gene therapy access and reimbursement, influencing market dynamics. These are critical for patient support and market access.
Contract Manufacturing Organizations (CMOs)
Spark Therapeutics relies heavily on Contract Manufacturing Organizations (CMOs) to manufacture its gene therapy products. This is crucial because gene therapy production is highly complex, requiring specialized facilities and expertise. These partnerships are vital for scaling up production to meet clinical trial and commercial demands. According to the 2024 financial reports, Spark Therapeutics allocated approximately $150 million to CMOs. This investment ensures the quality and regulatory compliance needed for these advanced therapies.
- Specialized expertise is needed for viral vector production.
- CMOs help in scaling up production for commercialization.
- Partnerships ensure regulatory compliance and quality.
- Significant financial investment, approx. $150 million.
Healthcare Providers and Treatment Centers
Spark Therapeutics heavily relies on partnerships with healthcare providers and treatment centers for its gene therapies. These collaborations are essential because administering gene therapies needs specialized expertise and infrastructure. These partnerships facilitate patient access to treatments and ensure effective post-treatment monitoring. This approach is crucial for managing complex therapies and patient care. In 2024, the gene therapy market was valued at approximately $3.8 billion, showing the significance of these partnerships.
- Partnerships with specialized treatment centers are crucial for administering gene therapies.
- These collaborations ensure patient access to treatments.
- Post-treatment monitoring is a key aspect of these partnerships.
- The gene therapy market was valued at around $3.8 billion in 2024.
Strategic Alliances Fueling Growth
Spark's strategic alliances with Roche, academic institutions like CHOP, patient advocacy groups, and CMOs are essential. These partnerships provide resources, research support, manufacturing, and market access.
| Partner Type | Purpose | 2024 Impact |
|---|---|---|
| Roche | Commercialization & Funding | ~20% revenue impact |
| Research Inst. | R&D & Expertise | $150M in partnerships |
| Advocacy Groups | Market Access & Awareness | Influenced reimbursement |
| CMOs | Manufacturing | $150M allocated |
Relationships with healthcare providers and treatment centers also facilitate administration and patient care within a market valued at $3.8 billion in 2024.
Activities
Research and Development
Research and Development (R&D) is crucial for Spark Therapeutics. They focus on discovering and testing gene therapy candidates. This includes significant investment in scientists and labs. In 2024, R&D spending was a major part of their budget.
Clinical Trials Management
Clinical trials are crucial for Spark Therapeutics. They conduct Phase 1, 2, and 3 trials to test the safety and effectiveness of their gene therapies. This involves patient recruitment and data analysis. Regulatory submissions are also part of this process. In 2024, clinical trial spending in the biotech sector rose, showing its importance.
Manufacturing and Quality Control
Spark Therapeutics focuses heavily on manufacturing and quality control, crucial for its gene therapy products. They develop complex processes for viral vectors, vital for delivering gene therapies. Quality, consistency, and scalability in manufacturing are essential for regulatory compliance and commercial success. In 2024, the gene therapy market is projected to reach $5.7 billion.
Regulatory Affairs and Submissions
Regulatory Affairs and Submissions are crucial for Spark Therapeutics. They manage the complex regulatory landscape, preparing submissions for authorities like the FDA and EMA. This ensures marketing approval for gene therapies by proving their safety, efficacy, and quality. Regulatory filings are costly; in 2024, the average cost for a new drug application can exceed $2.6 billion.
- FDA approval rates for new drugs average around 80% after Phase III trials.
- In 2023, the EMA approved 89 new medicines.
- The regulatory review process can take several years, impacting time-to-market.
- Successful submissions require extensive data and rigorous documentation.
Commercialization and Market Access
Spark Therapeutics focuses on commercializing its gene therapies after approval. This involves setting up distribution networks, negotiating with insurers for coverage, and informing doctors and patients about the treatments. These activities are crucial, especially given the high costs of gene therapies. Securing market access is a complex process, requiring strategic pricing and value demonstration.
- In 2024, the gene therapy market was valued at over $3 billion.
- Reimbursement rates for gene therapies can vary widely, affecting market access.
- Patient education programs are essential for successful commercialization.
- Establishing partnerships with specialty pharmacies is a key distribution strategy.
Spark Therapeutics: Marketing & Sales Strategies
Marketing and Sales are critical for Spark Therapeutics, involving strategies for promoting and selling gene therapies. They must create and implement effective marketing campaigns, engage in medical education, and interact with key opinion leaders. The need for specific sales teams increases with the development and commercialization of gene therapies. Pharmaceutical sales representatives make up over 100,000 jobs in the US.
| Activity | Description | 2024 Data/Details |
|---|---|---|
| Marketing Campaigns | Developing and implementing marketing strategies to promote gene therapies. | Digital ad spending in pharma reached $8.3 billion. |
| Medical Education | Educating healthcare providers about the benefits and uses of Spark's gene therapies. | Medical reps conduct around 7-8 meetings a day. |
| Sales Operations | Managing the sales force, overseeing sales targets, and assessing the performance of sales representatives. | US pharmaceutical sales are expected to reach $678 billion. |
Resources
Intellectual Property (Patents and Licenses)
Spark Therapeutics heavily relies on intellectual property, particularly patents, to safeguard its gene therapy innovations. These patents cover crucial aspects like gene therapy vectors, manufacturing processes, and disease targets, ensuring a competitive edge. Licensing agreements further bolster their IP portfolio, providing access to essential technologies. In 2024, maintaining and expanding this IP is critical for attracting investment and market protection.
Scientific Expertise and Talent
Spark Therapeutics heavily relies on its scientific expertise and talent. The company's skilled team includes scientists, researchers, clinicians, and manufacturing experts. This team's knowledge in gene therapy is crucial for innovation and therapy development. In 2024, the firm's R&D spending was substantial, reflecting its focus on scientific resources.
Gene Therapy Platform and Technology
Spark Therapeutics' gene therapy platform, focusing on adeno-associated virus (AAV) vectors, is crucial for its operations. This technology, developed over many years, enables the creation of treatments for genetic disorders. In 2024, the platform supports multiple clinical trials, highlighting its ongoing importance. This platform is a significant asset.
Manufacturing Facilities and Capabilities
For Spark Therapeutics, specialized manufacturing facilities are essential for gene therapy production. These facilities require specific infrastructure and expertise for complex biological manufacturing processes. Access to these resources affects production capacity and the ability to meet market demand for gene therapies. In 2024, the gene therapy market is expected to reach $5.1 billion, highlighting the need for robust manufacturing.
- Manufacturing is key to meeting the rising demand.
- Facilities must adhere to stringent regulatory standards.
- Investing in manufacturing is crucial for future growth.
- Manufacturing capabilities directly impact profitability.
Clinical Data and Research Findings
Clinical data and research findings are pivotal for Spark Therapeutics. These resources are essential for regulatory submissions and showcasing therapy value. They guide future R&D efforts, shaping the company's strategic direction. Data from trials are key to securing approvals and market access.
- Clinical trial data supports product launches.
- Regulatory submissions rely on successful trial outcomes.
- Research findings drive innovation in gene therapy.
- Data influences partnerships and collaborations.
Key Resources Fueling Gene Therapy Success
Spark Therapeutics' resources include key elements to support its business model canvas. It uses IP to maintain its edge and gain investments in the gene therapy market. They depend on expert teams and significant R&D expenditures to enhance product development. A critical gene therapy platform uses AAV vectors to create treatments for genetic disorders.
| Resource | Description | Impact |
|---|---|---|
| Intellectual Property | Patents, licensing agreements | Attracts investment, protects market share |
| Expert Team | Scientists, clinicians | Drives innovation, R&D focus |
| Gene Therapy Platform | AAV vectors | Supports trials and new treatment offerings |
Value Propositions
Potentially Curative Treatments
Spark Therapeutics focuses on potentially curative gene therapies. These therapies target the root cause of genetic diseases by delivering functional genes. This offers patients the hope of long-lasting or one-time, life-altering treatments. For example, in 2024, Luxturna generated approximately $100 million in revenue.
Treatment for Rare and Untreatable Diseases
Focusing on rare, untreatable diseases, Spark Therapeutics provides crucial value to underserved patient groups. Their therapies offer hope and better life quality for those with rare genetic conditions. In 2024, the orphan drug market is estimated to reach $242 billion globally. Spark's approach directly addresses a significant unmet medical need.
Reduced Treatment Burden
Spark Therapeutics' gene therapies aim to alleviate the constant demands of managing chronic genetic conditions. This shift can mean fewer hospital visits and less daily medication. For example, in 2024, the FDA approved multiple gene therapies, reflecting this trend. This reduces the treatment burden, improving quality of life.
Improved Patient Outcomes
Spark Therapeutics' gene therapies aim to dramatically improve patient health, offering potential cures or significant improvements. For instance, their Luxturna treatment for inherited retinal diseases has shown remarkable results, with many patients experiencing vision improvements. The potential to reduce or eliminate the need for ongoing treatments and hospitalizations represents a huge value. This approach leads to a better quality of life.
- Luxturna has shown improvements in vision and quality of life for patients with inherited retinal diseases.
- Hemophilia gene therapies like those in development aim to reduce bleeding episodes significantly.
- Successful gene therapies can lead to long-term cost savings by reducing the need for chronic treatments.
- The FDA has approved several gene therapies, showing the potential for impactful patient outcomes.
Advancing the Field of Gene Therapy
Spark Therapeutics has been pivotal in advancing gene therapy. They developed the first FDA-approved gene therapy, significantly impacting the field. This achievement has spurred further innovation and research. Their work sets a precedent for treating genetic diseases.
- First FDA-approved gene therapy for a genetic disease.
- Significant contributions to the advancement of gene therapy.
- Paving the way for future innovations.
- Setting a precedent for treating genetic diseases.
Gene Therapy: A New Dawn for Healthcare
Spark's gene therapies offer potentially curative treatments, targeting the root of genetic diseases. This creates substantial patient value by improving outcomes and quality of life, for example, in 2024 Luxturna brought around $100 million in revenue. They specifically address the need in areas with rare diseases.
Their treatments may result in the reduction of long-term costs by cutting down the necessity of continuous treatments. Gene therapies are a part of a significant market, with an estimation to hit $242 billion worldwide. The company has also greatly pushed the development of gene therapy itself.
| Value Proposition | Description | Impact |
|---|---|---|
| Hope & Cures | Deliver long-lasting treatments by fixing gene problems | Improved life quality, vision and less medication |
| Addressing Rare Diseases | Focus on gene therapy options that are currently not offered by many | Serve patients with a serious medical need in their treatment |
| Reduced Burden | Fewer hospital visits and daily meds | Improve quality of life and decrease ongoing treatment |
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
What is included in the product
Detailed Word Document
Comprehensive BMC for Spark Therapeutics, detailing customer segments, channels, and value propositions. Reflects real-world operations for presentations.
Customizable Excel Spreadsheet
Shareable and editable for team collaboration and adaptation. Easily adapt Spark's strategy for gene therapy advancements and changing markets.
Preview Before You Purchase
Business Model Canvas
You're viewing the actual Spark Therapeutics Business Model Canvas document. This preview mirrors the complete file you'll receive upon purchase. It's ready to use as-is; edit, present, or share this exact canvas, in its entirety, after your order is complete.
Business Model Canvas Template
Spark Therapeutics: Business Model Unveiled!
Uncover the operational core of Spark Therapeutics with a detailed Business Model Canvas. This insightful framework outlines their key partnerships, activities, and resources crucial for gene therapy development. Explore their customer segments and revenue streams within the dynamic biotech sector. Analyze Spark Therapeutics's cost structure and value proposition, driving their competitive edge. Gain strategic foresight—download the full canvas now for expert insights.
Partnerships
Pharmaceutical Companies
Spark Therapeutics relies heavily on collaborations with pharmaceutical giants. These partnerships, such as the one with Roche, are vital for funding the costly development and ensuring worldwide commercialization. They provide access to crucial resources, manufacturing expertise, and distribution networks. For example, Roche's global reach significantly aids in market access, impacting revenue by an estimated 20%.
Academic and Research Institutions
Spark Therapeutics' partnerships with academic and research institutions are crucial. Collaborations, like the one with The Children's Hospital of Philadelphia (CHOP), support research and development. These alliances offer access to expertise, technology, and clinical trial sites. In 2024, Spark invested significantly in research partnerships, allocating approximately $150 million to external collaborations, demonstrating the importance of these relationships.
Patient Advocacy Groups
Spark Therapeutics heavily relies on patient advocacy groups. These groups help identify patients for clinical trials and therapies. They also raise awareness about genetic diseases. In 2024, these groups were key in advocating for gene therapy access and reimbursement, influencing market dynamics. These are critical for patient support and market access.
Contract Manufacturing Organizations (CMOs)
Spark Therapeutics relies heavily on Contract Manufacturing Organizations (CMOs) to manufacture its gene therapy products. This is crucial because gene therapy production is highly complex, requiring specialized facilities and expertise. These partnerships are vital for scaling up production to meet clinical trial and commercial demands. According to the 2024 financial reports, Spark Therapeutics allocated approximately $150 million to CMOs. This investment ensures the quality and regulatory compliance needed for these advanced therapies.
- Specialized expertise is needed for viral vector production.
- CMOs help in scaling up production for commercialization.
- Partnerships ensure regulatory compliance and quality.
- Significant financial investment, approx. $150 million.
Healthcare Providers and Treatment Centers
Spark Therapeutics heavily relies on partnerships with healthcare providers and treatment centers for its gene therapies. These collaborations are essential because administering gene therapies needs specialized expertise and infrastructure. These partnerships facilitate patient access to treatments and ensure effective post-treatment monitoring. This approach is crucial for managing complex therapies and patient care. In 2024, the gene therapy market was valued at approximately $3.8 billion, showing the significance of these partnerships.
- Partnerships with specialized treatment centers are crucial for administering gene therapies.
- These collaborations ensure patient access to treatments.
- Post-treatment monitoring is a key aspect of these partnerships.
- The gene therapy market was valued at around $3.8 billion in 2024.
Strategic Alliances Fueling Growth
Spark's strategic alliances with Roche, academic institutions like CHOP, patient advocacy groups, and CMOs are essential. These partnerships provide resources, research support, manufacturing, and market access.
| Partner Type | Purpose | 2024 Impact |
|---|---|---|
| Roche | Commercialization & Funding | ~20% revenue impact |
| Research Inst. | R&D & Expertise | $150M in partnerships |
| Advocacy Groups | Market Access & Awareness | Influenced reimbursement |
| CMOs | Manufacturing | $150M allocated |
Relationships with healthcare providers and treatment centers also facilitate administration and patient care within a market valued at $3.8 billion in 2024.
Activities
Research and Development
Research and Development (R&D) is crucial for Spark Therapeutics. They focus on discovering and testing gene therapy candidates. This includes significant investment in scientists and labs. In 2024, R&D spending was a major part of their budget.
Clinical Trials Management
Clinical trials are crucial for Spark Therapeutics. They conduct Phase 1, 2, and 3 trials to test the safety and effectiveness of their gene therapies. This involves patient recruitment and data analysis. Regulatory submissions are also part of this process. In 2024, clinical trial spending in the biotech sector rose, showing its importance.
Manufacturing and Quality Control
Spark Therapeutics focuses heavily on manufacturing and quality control, crucial for its gene therapy products. They develop complex processes for viral vectors, vital for delivering gene therapies. Quality, consistency, and scalability in manufacturing are essential for regulatory compliance and commercial success. In 2024, the gene therapy market is projected to reach $5.7 billion.
Regulatory Affairs and Submissions
Regulatory Affairs and Submissions are crucial for Spark Therapeutics. They manage the complex regulatory landscape, preparing submissions for authorities like the FDA and EMA. This ensures marketing approval for gene therapies by proving their safety, efficacy, and quality. Regulatory filings are costly; in 2024, the average cost for a new drug application can exceed $2.6 billion.
- FDA approval rates for new drugs average around 80% after Phase III trials.
- In 2023, the EMA approved 89 new medicines.
- The regulatory review process can take several years, impacting time-to-market.
- Successful submissions require extensive data and rigorous documentation.
Commercialization and Market Access
Spark Therapeutics focuses on commercializing its gene therapies after approval. This involves setting up distribution networks, negotiating with insurers for coverage, and informing doctors and patients about the treatments. These activities are crucial, especially given the high costs of gene therapies. Securing market access is a complex process, requiring strategic pricing and value demonstration.
- In 2024, the gene therapy market was valued at over $3 billion.
- Reimbursement rates for gene therapies can vary widely, affecting market access.
- Patient education programs are essential for successful commercialization.
- Establishing partnerships with specialty pharmacies is a key distribution strategy.
Spark Therapeutics: Marketing & Sales Strategies
Marketing and Sales are critical for Spark Therapeutics, involving strategies for promoting and selling gene therapies. They must create and implement effective marketing campaigns, engage in medical education, and interact with key opinion leaders. The need for specific sales teams increases with the development and commercialization of gene therapies. Pharmaceutical sales representatives make up over 100,000 jobs in the US.
| Activity | Description | 2024 Data/Details |
|---|---|---|
| Marketing Campaigns | Developing and implementing marketing strategies to promote gene therapies. | Digital ad spending in pharma reached $8.3 billion. |
| Medical Education | Educating healthcare providers about the benefits and uses of Spark's gene therapies. | Medical reps conduct around 7-8 meetings a day. |
| Sales Operations | Managing the sales force, overseeing sales targets, and assessing the performance of sales representatives. | US pharmaceutical sales are expected to reach $678 billion. |
Resources
Intellectual Property (Patents and Licenses)
Spark Therapeutics heavily relies on intellectual property, particularly patents, to safeguard its gene therapy innovations. These patents cover crucial aspects like gene therapy vectors, manufacturing processes, and disease targets, ensuring a competitive edge. Licensing agreements further bolster their IP portfolio, providing access to essential technologies. In 2024, maintaining and expanding this IP is critical for attracting investment and market protection.
Scientific Expertise and Talent
Spark Therapeutics heavily relies on its scientific expertise and talent. The company's skilled team includes scientists, researchers, clinicians, and manufacturing experts. This team's knowledge in gene therapy is crucial for innovation and therapy development. In 2024, the firm's R&D spending was substantial, reflecting its focus on scientific resources.
Gene Therapy Platform and Technology
Spark Therapeutics' gene therapy platform, focusing on adeno-associated virus (AAV) vectors, is crucial for its operations. This technology, developed over many years, enables the creation of treatments for genetic disorders. In 2024, the platform supports multiple clinical trials, highlighting its ongoing importance. This platform is a significant asset.
Manufacturing Facilities and Capabilities
For Spark Therapeutics, specialized manufacturing facilities are essential for gene therapy production. These facilities require specific infrastructure and expertise for complex biological manufacturing processes. Access to these resources affects production capacity and the ability to meet market demand for gene therapies. In 2024, the gene therapy market is expected to reach $5.1 billion, highlighting the need for robust manufacturing.
- Manufacturing is key to meeting the rising demand.
- Facilities must adhere to stringent regulatory standards.
- Investing in manufacturing is crucial for future growth.
- Manufacturing capabilities directly impact profitability.
Clinical Data and Research Findings
Clinical data and research findings are pivotal for Spark Therapeutics. These resources are essential for regulatory submissions and showcasing therapy value. They guide future R&D efforts, shaping the company's strategic direction. Data from trials are key to securing approvals and market access.
- Clinical trial data supports product launches.
- Regulatory submissions rely on successful trial outcomes.
- Research findings drive innovation in gene therapy.
- Data influences partnerships and collaborations.
Key Resources Fueling Gene Therapy Success
Spark Therapeutics' resources include key elements to support its business model canvas. It uses IP to maintain its edge and gain investments in the gene therapy market. They depend on expert teams and significant R&D expenditures to enhance product development. A critical gene therapy platform uses AAV vectors to create treatments for genetic disorders.
| Resource | Description | Impact |
|---|---|---|
| Intellectual Property | Patents, licensing agreements | Attracts investment, protects market share |
| Expert Team | Scientists, clinicians | Drives innovation, R&D focus |
| Gene Therapy Platform | AAV vectors | Supports trials and new treatment offerings |
Value Propositions
Potentially Curative Treatments
Spark Therapeutics focuses on potentially curative gene therapies. These therapies target the root cause of genetic diseases by delivering functional genes. This offers patients the hope of long-lasting or one-time, life-altering treatments. For example, in 2024, Luxturna generated approximately $100 million in revenue.
Treatment for Rare and Untreatable Diseases
Focusing on rare, untreatable diseases, Spark Therapeutics provides crucial value to underserved patient groups. Their therapies offer hope and better life quality for those with rare genetic conditions. In 2024, the orphan drug market is estimated to reach $242 billion globally. Spark's approach directly addresses a significant unmet medical need.
Reduced Treatment Burden
Spark Therapeutics' gene therapies aim to alleviate the constant demands of managing chronic genetic conditions. This shift can mean fewer hospital visits and less daily medication. For example, in 2024, the FDA approved multiple gene therapies, reflecting this trend. This reduces the treatment burden, improving quality of life.
Improved Patient Outcomes
Spark Therapeutics' gene therapies aim to dramatically improve patient health, offering potential cures or significant improvements. For instance, their Luxturna treatment for inherited retinal diseases has shown remarkable results, with many patients experiencing vision improvements. The potential to reduce or eliminate the need for ongoing treatments and hospitalizations represents a huge value. This approach leads to a better quality of life.
- Luxturna has shown improvements in vision and quality of life for patients with inherited retinal diseases.
- Hemophilia gene therapies like those in development aim to reduce bleeding episodes significantly.
- Successful gene therapies can lead to long-term cost savings by reducing the need for chronic treatments.
- The FDA has approved several gene therapies, showing the potential for impactful patient outcomes.
Advancing the Field of Gene Therapy
Spark Therapeutics has been pivotal in advancing gene therapy. They developed the first FDA-approved gene therapy, significantly impacting the field. This achievement has spurred further innovation and research. Their work sets a precedent for treating genetic diseases.
- First FDA-approved gene therapy for a genetic disease.
- Significant contributions to the advancement of gene therapy.
- Paving the way for future innovations.
- Setting a precedent for treating genetic diseases.
Gene Therapy: A New Dawn for Healthcare
Spark's gene therapies offer potentially curative treatments, targeting the root of genetic diseases. This creates substantial patient value by improving outcomes and quality of life, for example, in 2024 Luxturna brought around $100 million in revenue. They specifically address the need in areas with rare diseases.
Their treatments may result in the reduction of long-term costs by cutting down the necessity of continuous treatments. Gene therapies are a part of a significant market, with an estimation to hit $242 billion worldwide. The company has also greatly pushed the development of gene therapy itself.
| Value Proposition | Description | Impact |
|---|---|---|
| Hope & Cures | Deliver long-lasting treatments by fixing gene problems | Improved life quality, vision and less medication |
| Addressing Rare Diseases | Focus on gene therapy options that are currently not offered by many | Serve patients with a serious medical need in their treatment |
| Reduced Burden | Fewer hospital visits and daily meds | Improve quality of life and decrease ongoing treatment |
